TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00821236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer Laser
Description: WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO/VISX CustomVue™
Description: Excimer Laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LADARVision 4000 excimer laser
Description: Excimer Laser
Study: NCT04007809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).
Study: NCT03297541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: m-health approach
Description: Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981). Anthropometric and demographic data collected on children in the dyad only.
Study: NCT01132261

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brain preservation' diet
Description: dietetic evaluation and advice in small group for health diet
Study: NCT03647722

Intervention type: OTHER
Intervention: Assessment of leukocyte function.
Description: The function and phenotype of regulatory B-cells, regulatory T-cells and alternatively-activated monocytes will be assessed directly ex vivo from PBMC.
Study: NCT04076527

Intervention type: DRUG
Intervention: UDCA
Description: Routine data is collected for UDCA therapy.

Intervention type: DRUG
Intervention: UDCA
Description: Routine data is collected for UDCA therapy.

Intervention type: DRUG
Intervention: UDCA
Description: Routine data is collected for UDCA therapy.

Intervention type: DRUG
Intervention: Ocaliva
Description: Routine data is collected for OCA therapy.

Intervention type: DRUG
Intervention: Ocaliva
Description: Routine data is collected for OCA therapy.
Study: NCT04391413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of OCT to guide the angioplasty procedure
Description: OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
Study: NCT04992442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Oral Tablet
Description: TAK-935 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-935 IV Infusion
Description: \[14C\]TAK-935 IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-935 Oral Solution
Description: \[14C\]TAK-935 oral solution
Study: NCT04858620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xlear Nasal Spray
Description: Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nostrils, every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline nasal spray, 2 puffs per nostrils, every 6 hours
Study: NCT00764972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and Vinorelbine
Description: vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe.
Study: NCT01856491

Intervention type: DEVICE
Group type: OTHER
Intervention: RELIANCE 4-FRONT™ Passive Fixation lead implantation
Description: Implantation of transvenous defibrillation lead with passive fixation mechanism.
Study: NCT00222729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 day 1 q 21 days
Study: NCT03111069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery
Description: Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery
Description: Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-Operative Radiation
Description: Standard dose brachytherapy delivered to the residual pelvic tumor sites.
Study: NCT01231854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alitretinoin
Description: In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
Study: NCT03300531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection
Description: Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided platelet-rich-plasma (PRP) injection
Description: Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Compound betamethasone injection
Description: Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
Study: NCT03436810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Task-Oriented Circuit Class Training
Description: Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Task-Oriented Circuit Class Training
Description: Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
Study: NCT02088242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
Study: NCT02568137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart-phone based technology
Study: NCT01568788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine
Description: 200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine of Pasteur
Description: 200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine of GSK
Description: 200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
Study: NCT02301611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLPLDC
Description: Autologous tumor lysate, particle-loaded dendritic cell vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00620789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram + CBT-I
Description: * Escitalopram, 10 mg daily for the duration of the study (6 months)~* CBT-I, four biweekly sessions during eight week Treatment phase.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT-I plus placebo antidepressant medication
Description: * CBT-I, 4 biweekly sessions, eight week Treatment phase.~* Placebo,daily for duration of study(6 months).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Escitalopram
Description: * Escitalopram, 10 mg daily for the duration of the study (6 months)~* SH, four biweekly sessions during eight week Treatment phase
Study: NCT02636842

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole Lauroxil
Description: Intramuscular (IM) injection, single dose
Study: NCT04147572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tiotropium inhalation powder type A
Description: Placebo inhalation from inhaler A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spiriva capsule
Description: Placebo inhalation from HandiHaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tiotropium inhalation powder type B
Description: Placebo inhalation from inhaler B

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Substudy Placebo Tiotropium Easyhaler
Description: Substudy placebo inhalation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Substudy Placebo Spiriva® via HandiHaler
Description: Substudy placebo inhalation
Study: NCT00847639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
Study: NCT02917993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80 mg once daily (QD)
Study: NCT04019587

Intervention type: DIAGNOSTIC_TEST
Intervention: Fear of Falling Avoidance Behavior Questionnaire administration
Description: The Questionnaire includes 14 items dealing with avoidance behavior. All items will be asked by face to face technique.
Study: NCT03601000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yi-Zhi-An-Shen
Description: Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules 5g given three times a day for up to 16 weeks.
Study: NCT00701376

Intervention type: OTHER
Group type: OTHER
Intervention: liver biopsy
Description: Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
Study: NCT03128645

Intervention type: DEVICE
Intervention: Abdominal Corset
Description: The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.

Intervention type: DEVICE
Intervention: Abdominal Corset
Description: The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
Study: NCT02801344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal
Description: test drink which contains low amount of amino acids (0.14 g/kg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate
Description: test drink which contains moderate amount of amino acids (0.40 g/kg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High
Description: test drink which contains high amount of amino acids (1.03 g/kg/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled-diet
Description: the diet containing 0.8 g protein /kg/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled-diet
Description: the diet containing 0.8 g protein /kg/day
Study: NCT02745769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT01359410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh reinforced staple line (SEAMGUARD)
Description: Reinforce the pancreatic transaction with SEAMGUARD®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled without mesh reinforcement (PER-STRIPS DRY)
Description: Stapled without mesh reinforcement (PERI-STRIPS DRY®)
Study: NCT00994279

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Yoga sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Educational Wellness Group
Study: NCT03923387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MynxGrip
Description: Vascular Closure
Study: NCT02801344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled-diet
Description: the diet containing 0.8 g protein /kg/day
Study: NCT03923387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Manual compression is a commonly used method to achieve hemostasis of femoral artery
Study: NCT00693030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)
Description: comparison of multiple drug eluting stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)
Description: comparison of multiple drug eluting coronary stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)
Description: comparison of multiple drug eluting coronary stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)
Description: comparison of DES in overlap vs BMS in overlap
Study: NCT03445481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medacta femoral prosthesis
Description: patients' treatment with a new implant prosthesis
Study: NCT03936322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive fetoscopic repair of MMC
Description: Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
Study: NCT00859014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells
Description: Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
Study: NCT00162942

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adacolumn
Description: Ten apheresis sessions:~One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham, ten apheresis sessions within 9 weeks
Study: NCT02179645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 27864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02723656

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Referral NYS Quitline
Description: Care coordinator will make an online referral to the NYS Quitline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco cessation counseling and coordination of cessation medications
Description: Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
Study: NCT03496961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yan Nian Jiu Zhuan Fa
Description: Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
Study: NCT01554228

Intervention type: OTHER
Intervention: Observation
Description: Observational study to examine changes in cognition following bariatric surgery after one year.
Study: NCT02788474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03496961

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yan Nian Jiu Zhuan Fa
Description: Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
Study: NCT04502927

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Passive extension mobilization of the hand and wrist joints
Description: The physiotherapist will proceed with the passive mobilization of the spastic hand of the stroke patient or the dominant hand for healthy volunteers.~Two mobilizations will be performed for each participant, i.e. one for each type of medial or lateral grip. The order of mobilization will be determined by randomization.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Passive extension mobilization of the hand and wrist joints
Description: The physiotherapist will proceed with the passive mobilization of the spastic hand of the stroke patient or the dominant hand for healthy volunteers.~Two mobilizations will be performed for each participant, i.e. one for each type of medial or lateral grip. The order of mobilization will be determined by randomization.
Study: NCT02888795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic dextrose prolotherapy
Description: five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
Study: NCT02931162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion
Description: Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham herb-partitioned moxibustion
Description: Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
Study: NCT00843362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal pessary
Description: 10 mg controlled-release dinoprostone pessary applied for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone vaginal gel
Description: 2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
Study: NCT04700319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19/CD20 CAR-T cell infusion
Description: CD19/CD20 CAR-T,Infusion,iv,0.2×10\^6-5×10\^6γδT /kg,once
Study: NCT01575145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline facilitation intervention
Description: brief quitline facilitation intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief stop-smoking intervention
Description: brief review of tips to help maintain smoking abstinence, using brochure